Dietary standing and survival of 8247 most cancers sufferers with or with out diabetes mellitus-results from a potential cohort examine
Background: The variety of most cancers sufferers with diabetes mellitus (DM) is steadily rising. Little is thought in regards to the dietary standing of this inhabitants. This examine characterised the dietary standing and survival of most cancers sufferers with diabetes in contrast with these with out diabetes.
Strategies: A complete of 8247 most cancers sufferers had been prospectively enrolled from 72 hospitals in China and adopted till August 2019. A worldwide estimation of the dietary standing was carried out for every participant utilizing standardized instruments. The outcomes had been cancer-specific survival (CSS) and general survival (OS).
Outcomes: The incidence of diabetes was 7.6% in the entire inhabitants. Compared with the non-DM group, the DM group had larger physique weight, however the same fat-free mass, a decrease handgrip energy and a decreased Karnofsky efficiency rating. A better proportion of sufferers with diabetes had been chubby/overweight as indicated by BMI. The proportion of sufferers who had been prone to malnutrition (evaluated by PG-SGA) was larger within the DM group (rating ≥ 4, 56.7% vs 52.9%). Sufferers with DM confirmed a worse CSS (4-year CSS, 62% vs 73%) and OS (4-year OS 39% vs 52%). Diabetes was related to an elevated threat of each cancer-specific (hazard ratio (HR) = 1.282, 95% confidence interval (CI) 1.070-1.536) and general (HR = 1.206, 95% CI 1.040-1.399) mortality.
Conclusions: Most cancers sufferers with diabetes had a bigger physique mass however decrease muscle energy, poorer efficiency standing and better incidence of malnourishment. Diabetes was related to compromised survival. Tailor-made dietary intervention is important for this subpopulation of sufferers.
.

VEGF-A(VEGF/1063) Antibody |
|||
BNC801063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC811063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC811063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC701063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC701063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC881063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC881063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC051063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC051063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC041063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC041063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC401063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC401063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCB1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCB1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCAP1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCAP1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCA1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCR1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCP1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNUM1063-50 | Biotium | 50uL | EUR 474 |
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCH1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNCH1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNUB1063-100 | Biotium | 100uL | EUR 250.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNUB1063-500 | Biotium | 500uL | EUR 549.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC611063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC611063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC551063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC551063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC431063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC431063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC681063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC681063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC471063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
|||
BNC471063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
Anti-VEGF/Vegfa Antibody |
|||
A00045 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-VEGF/Vegfa Antibody |
|||
A00045-2 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-VEGF/VEGFA Antibody |
|||
PB9071 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-VEGF/VEGFA Antibody |
|||
PA1080 | BosterBio | 100ug/vial | EUR 400.8 |
VEGF antibody |
|||
10-2585 | Fitzgerald | 250 ug | EUR 590.4 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
10-2586 | Fitzgerald | 100 ug | EUR 289.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
10R-7735 | Fitzgerald | 500 ug | EUR 678 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
10R-V101ax | Fitzgerald | 100 ug | EUR 571.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
10R-V101b | Fitzgerald | 200 ug | EUR 805.2 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
10R-V109A | Fitzgerald | 500 ug | EUR 327.6 |
Description: Mouse monoclonal VEGF antibody |
VEGF antibody |
|||
70R-VG001 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Affinity purified Goat polyclonal VEGF antibody |
VEGF antibody |
|||
70R-VR001x | Fitzgerald | 50 ug | EUR 392.4 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-VR003 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-VR004 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-VR006 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70-VR20 | Fitzgerald | 50 ug | EUR 392.4 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-11863 | Fitzgerald | 100 ul | EUR 536.4 |
Description: Goat polyclonal VEGF antibody |
VEGF antibody |
|||
70R-11864 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
VEGF Antibody |
|||
5363-100 | Biovision | each | EUR 398.4 |
VEGF Antibody |
|||
5363-30T | Biovision | each | EUR 175.2 |
VEGF Antibody |
|||
5365-100 | Biovision | each | EUR 379.2 |
VEGF Antibody |
|||
5365-30T | Biovision | each | EUR 175.2 |
VEGF antibody |
|||
70R-12327 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-12328 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-12329 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
VEGF antibody |
|||
70R-13764 | Fitzgerald | 100 ug | EUR 418.8 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
VEGF Antibody |
|||
48707-100ul | SAB | 100ul | EUR 399.6 |
VEGF Antibody |
|||
48707-50ul | SAB | 50ul | EUR 286.8 |
VEGF Antibody |
|||
ABF5131 | Lifescience Market | 100 ug | EUR 525.6 |
VEGF antibody |
|||
PAab09933 | Lifescience Market | 100 ug | EUR 463.2 |
VEGF Antibody |
|||
R31500 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: VEGF is the only mitogen that specifically acts on endothelial cells. It may be a major regulator of tumor angiogenesis in vivo. It is structurally related to platelet-derived growth factor. VEGF shares homology with the PDGF A chain and B chain, including conservation of all 8 cysteines found in PDGFA and PDGFB. VEGF gene contains 8 exons. VEGF induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. And this gene also can regulate haematopoietic stem cell survival by an internal autocrine loop mechanism. What’s more, it also stimulates neurogenesis in vitro and in vivo. |
VEGF Antibody |
|||
V8154-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
VEGF Antibody |
|||
V8154-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
VEGF Antibody |
|||
V8154SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. |
VEGF/ Rat VEGF ELISA Kit |
|||
ELA-E0143r | Lifescience Market | 96 Tests | EUR 1063.2 |
VEGF |
|||
MO15067 | Neuromics | 500 ug | EUR 1092 |
VEGF |
|||
LF-PR009 | Abfrontier | 10 ug | EUR 306 |
Description: VEGF protein |
VEGF |
|||
PR15028 | Neuromics | 10 ug | EUR 553.2 |
VEGF 121 |
|||
PR15029 | Neuromics | 5 ug | EUR 498 |
VEGF 162 |
|||
PR15030 | Neuromics | 25 ug | EUR 553.2 |
VEGF 165 |
|||
PR15031 | Neuromics | 50 ug | EUR 1477.2 |
VEGF 120 |
|||
PR15033 | Neuromics | 5 ug | EUR 459.6 |
VEGF 164 |
|||
PR15034 | Neuromics | 25 ug | EUR 1352.4 |
VEGF 164 |
|||
PR15035 | Neuromics | 50 ug | EUR 1477.2 |
Human VEGF 121 Antibody |
|||
32562-05111 | AssayPro | 150 ug | EUR 313.2 |
Human VEGF 165 Antibody |
|||
32563-05111 | AssayPro | 150 ug | EUR 313.2 |
EG VEGF antibody |
|||
20R-1607 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Rabbit polyclonal EG VEGF antibody |
VEGF C antibody |
|||
20R-1831 | Fitzgerald | 100 ug | EUR 807.6 |
Description: Goat polyclonal VEGF C antibody |
EG VEGF antibody |
|||
70R-EG002 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Goat polyclonal EG VEGF antibody |
VEGF-C Antibody |
|||
5633-100 | Biovision | each | EUR 444 |
VEGF-C Antibody |
|||
5633R-100 | Biovision | each | EUR 379.2 |
VEGF-C Antibody |
|||
5633R-30T | Biovision | each | EUR 175.2 |
VEGF-C Antibody |
|||
5634-100 | Biovision | each | EUR 379.2 |
VEGF-C Antibody |
|||
5634-30T | Biovision | each | EUR 175.2 |
Impression of diabetes mellitus on feminine topics present process transcatheter aortic valve implantation: Insights from the WIN-TAVI worldwide registry
Background: Feminine topics represent half of all transcatheter aortic valve implantation (TAVI) candidates, however the affiliation between necessary comorbidities resembling diabetes mellitus (DM) and medical outcomes after TAVI stays unclear on this group.
Methodology: WIN-TAVI is a real-world worldwide registry of solely feminine topics present process TAVI. The examine inhabitants was stratified into these with (DM) and people with out DM (NDM). Valve Educational Analysis Consortium (VARC)-2 efficacy (composite of all-cause dying, stroke, myocardial infarction, hospitalization for valve-related signs or worsening congestive coronary heart failure, or valve-related dysfunction) was the first endpoint for this evaluation.
Outcomes: Of the 1012 topics included on this examine, 264 (26.1%) had DM at baseline. DM sufferers had been youthful however had a better burden of comorbidities. There have been no variations in VARC-2 efficacy occasions between DM and NDM sufferers at 30 days or 1 yr. Conversely, sufferers with DM had a decrease threat of VARC-2 life threatening bleeding at 30 days and 1 yr after TAVI in comparison with NDM sufferers, which remained important even after multivariable adjustment (HR, 0.34, 95% CI, 0.12-0.99; p = .047). Within the subgroup evaluation, insulin-dependent DM was not related to an elevated threat of hostile outcomes.
Conclusions: Amongst feminine sufferers present process TAVI, greater than one-fourth of the themes offered with DM. At 1-year follow-up, DM was related to decrease bleeding issues and no improve within the threat of different hostile occasions, together with mortality, after TAVI.
The Position of Diabetes Mellitus as an Impact Modifier of the Affiliation Between Smoking Cessation and Its Medical Prognoses: An Observational Cohort Research
The smoker’s paradox refers to an elevated threat of hostile medical outcomes after smoking cessation in sufferers with coronary artery illness. The mechanisms concerned are controversial. The current examine evaluated the impact of delay in smoking cessation on medical outcomes amongst sufferers after percutaneous coronary intervention (PCI) stratified by diabetes mellitus (DM). Sufferers included on this examine got here from a longtime Fu Wai hospital PCI cohort. Smoking conduct was recorded; medical finish factors included all-cause mortality and repeat revascularization.
The analyses had been based mostly on 8489 people who smoke who underwent PCI. Sufferers with and with out DM had been examined individually. Multivariable mannequin evaluation urged that smoking cessation was related to important decrease all-cause mortality each for non-DM and DM sufferers. The smoking paradox was noticed for revascularization. Nonetheless, the elevated threat of repeat revascularization correlated with quitting time amongst non-DM sufferers solely, particularly in the event that they stopped smoking late (>90 days) after their index process (adjusted hazard ratio, 3.40; 95% CI: 2.45-4.72). In conclusion, smoking cessation is related to a decrease mortality fee for PCI sufferers. Nonetheless, the relative profit on repeated revascularization was solely noticed amongst non-DM sufferers in the event that they stop smoking early.
GRO, KC, CXCL1, rRtGRO, rat |
|||
RC352-12 | Bio Basic | 5ug | EUR 125.26 |
Mouse CXC-chemokine ligand 1(CXCL1/KC)ELISA Kit |
|||
YLA0122MO-48T | Shanghai YL Biotech | 48T | EUR 465 |
Mouse CXC-chemokine ligand 1(CXCL1/KC)ELISA Kit |
|||
YLA0122MO-96T | Shanghai YL Biotech | 96T | EUR 600 |
GRO/KC (CXCL1), Rat Recombinant |
|||
P1288-25 | Biovision | each | EUR 444 |
GRO/KC (CXCL1), Rat Recombinant |
|||
P1288-5 | Biovision | each | EUR 210 |
Recombinant Murine KC (CXCL1) Protein |
|||
PROTP12850-2 | BosterBio | 20ug | EUR 380.4 |
Description: All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors. The GRO proteins chemoattract and activate neutrophils and basophils. Recombinant murine KC is a 7.8 kDa protein consisting of 72 amino acids including the 'ELR' motif common to the CXC chemokine family that bind to CXCR1 or CXCR2. |
Recombinant Rat GRO/KC (CXCL1) Protein |
|||
PROTP14095-1 | BosterBio | 25ug | EUR 380.4 |
Description: All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors. The GRO proteins chemoattract and activate neutrophils and basophils. Recombinant rat GRO/KC is a 7.8 kDa protein consisting of 72 amino acids including the 'ELR' motif common to the CXC chemokine family that bind to CXCR1 or CXCR2. |
Rat CXCL1/CINC-1/KC ELISA Kit |
|||
RK00196 | Abclonal | 96 Tests | EUR 625.2 |
Rabbit Anti Mouse Cxcl1 Polyclonal Antibody |
|||
CPBT-65100RM | Creative Diagnostics | 0.1 mg | EUR 1057.2 |
Mouse CXCL1 ELISA Kit |
|||
55R-1741 | Fitzgerald | 1 kit | EUR 748.8 |
Description: ELISA kit for detection of CXCL1 in the research laboratory |
Mouse CXCL1 shRNA Plasmid |
|||
20-abx970673 | Abbexa |
|
|
GRO-alpha/CXCL1, Mouse |
|||
HY-P7188 | MedChemExpress | 50ug | EUR 639.6 |
ELISA kit for Mouse CXCL1 |
|||
EK5299 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL1 in samples from serum, plasma, tissue homogenates and other biological fluids. |
Mouse CXCL1/GROα ELISA kit |
|||
LF-EK50473 | Abfrontier | 1×96T | EUR 777.6 |
Mouse CXCL1 PicoKine ELISA Kit |
|||
EK0723 | BosterBio | 96 wells | EUR 547.2 |
Description: For quantitative detection of mouse CXCL1 in cell culture supernates and serum. |
Mouse CXCL1 Detection Assay Kit |
|||
6725 | Chondrex | 1 kit | EUR 580.26 |
Description: Mouse CXCL1 Detection Assay Kit |
CXCL1 protein (Mouse) (His tag) |
|||
80R-3368 | Fitzgerald | 50 ug | EUR 308.4 |
Description: Purified recombinant CXCL1 protein (Mouse) (His tag) |
CXCL1 protein (Mouse) (His tag) |
|||
80R-3439 | Fitzgerald | 50 ug | EUR 308.4 |
Description: Purified recombinant CXCL1 protein (Mouse) (His tag) |
Cxcl1 ORF Vector (Mouse) (pORF) |
|||
ORF042286 | ABM | 1.0 ug DNA | EUR 114 |
Mouse CXCL1 AssayLite Antibody (FITC Conjugate) |
|||
70027-05141 | AssayPro | 150 ug | EUR 513.6 |
CXCL1 ELISA Kit (Mouse) (OKBB00312) |
|||
OKBB00312 | Aviva Systems Biology | 96 Tests | EUR 652.8 |
Description: Description of target: Chemokine (C-X-C motif) ligand 1 (CXCL1) is a small cytokine belonging to the CXC chemokine family that was previously called GRO1 oncogene, GROα, KC, Neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α). In humans, this protein is encoded by the CXCL1 gene. The gene for CXCL1 is located on human chromosome 4 amongst genes for other CXC chemokines. The mature form of CXCL1 is maximally 73 amino acids long. CXCL1 is secreted by human melanoma cells, has mitogenic properties and is implicated in melanoma pathogenesis. CXCL1 is expressed by macrophages, neutrophils and epithelial cells, and has neutrophil chemoattractant activity. This chemokine elicits its effects by signaling through the chemokine receptor CXCR2.CXCL1 decreased the severity of multiple sclerosis and may offer a neuro-protective function. The standard product used in this kit is recombinant mouse CXCL1, consisting of 77 amino acids with the molecular mass of 8KDa.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: < 1 pg/ml |
CXCL1 ELISA Kit (Mouse) (OKAN04583) |
|||
OKAN04583 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
Description: Description of target: This gene encodes a protein that is a member of the CXC subfamily of chemokines. Chemokines, which recruit and activate leukocytes, are classified by function (inflammatory or homeostatic) or by structure. This secretory protein is proposed to bind the G-protein coupled receptor chemokine (C-X-C motif) receptor 2 to recruit neutrophils. In mouse, deficiency of this gene is associated with colitis and with defects in immune cell recruitment to the lung.;Species reactivity: Mouse;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 6.0 pg/mL |
CXCL1 ELISA Kit (Mouse) (OKCD05712) |
|||
OKCD05712 | Aviva Systems Biology | 96 Wells | EUR 730.8 |
Description: Description of target: This gene encodes a protein that is a member of the CXC subfamily of chemokines. Chemokines, which recruit and activate leukocytes, are classified by function (inflammatory or homeostatic) or by structure. This secretory protein is proposed to bind the G-protein coupled receptor chemokine (C-X-C motif) receptor 2 to recruit neutrophils. In mouse, deficiency of this gene is associated with colitis and with defects in immune cell recruitment to the lung.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: < 6.0pg/mL |
Mouse CXCL1/GROα ELISA kit (4X96T) |
|||
LF-EK50474 | Abfrontier | 4×96T | EUR 2641.2 |
Anti-GRO alpha/Cxcl1 Antibody |
|||
A00533 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-GRO alpha/CXCL1 Antibody |
|||
PA1760 | BosterBio | 100ug/vial | EUR 352.8 |
CXCL1 Antibody |
|||
43679-100ul | SAB | 100ul | EUR 302.4 |
CXCL1 antibody |
|||
70R-10502 | Fitzgerald | 50 ug | EUR 560.4 |
Description: Affinity purified rabbit polyclonal CXCL1 antibody |
CXCL1 antibody |
|||
70R-14297 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Affinity purified Rabbit polyclonal CXCL1 antibody |
CXCL1 antibody |
|||
70R-16681 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal CXCL1 antibody |
CXCL1 antibody |
|||
70R-15473 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal CXCL1 antibody |
CXCL1 Antibody |
|||
33054-100ul | SAB | 100ul | EUR 302.4 |
CXCL1 Antibody |
|||
1-CSB-PA006239GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
CXCL1 Antibody |
|||
1-CSB-PA06097A0Rb | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA |
CXCL1 Antibody |
|||
1-CSB-PA009036 | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000 |
Cxcl1 Antibody |
|||
1-CSB-PA09217A0Rb | Cusabio |
|
|
Description: A polyclonal antibody against Cxcl1. Recognizes Cxcl1 from Mouse. This antibody is Unconjugated. Tested in the following application: ELISA |
GRO-alpha/CXCL1 (CHO-expressed), Mouse |
|||
HY-P7186 | MedChemExpress | 50ug | EUR 404.4 |
Cxcl1 sgRNA CRISPR Lentivector set (Mouse) |
|||
K4368201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Mouse Growth-regulated alpha protein (Cxcl1) |
|||
1-CSB-RP092174m | Cusabio |
|
|
Description: Recombinant Mouse Growth-regulated alpha protein(Cxcl1),partial expressed in E.coli |
CXCL1 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV169144 | ABM | 500 ng | EUR 723.6 |
Cxcl1 ELISA Kit (Mouse) : 96 Wells (OKEH02714) |
|||
OKEH02714 | Aviva Systems Biology | 96 Wells | EUR 652.8 |
Description: Description of target: This gene encodes a protein that is a member of the CXC subfamily of chemokines. Chemokines, which recruit and activate leukocytes, are classified by function (inflammatory or homeostatic) or by structure. This secretory protein is proposed to bind the G-protein coupled receptor chemokine (C-X-C motif) receptor 2 to recruit neutrophils. In mouse, deficiency of this gene is associated with colitis and with defects in immune cell recruitment to the lung. ;Species reactivity: Mouse;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 15.76 pg/mL |
CXCL1 Protein Vector (Mouse) (pPB-C-His) |
|||
PV169142 | ABM | 500 ng | EUR 723.6 |
CXCL1 Protein Vector (Mouse) (pPB-N-His) |
|||
PV169143 | ABM | 500 ng | EUR 723.6 |
CXCL1 Protein Vector (Mouse) (pPM-C-His) |
|||
PV169145 | ABM | 500 ng | EUR 723.6 |
Nori® Mouse CXCL1/GRO-alpha ELISA Kit |
|||
GR117324 | Genorise Scientific | 96-well | EUR 461 |
CXCL1 antibody (HRP) |
|||
60R-2236 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal CXCL1 antibody (HRP) |
Rabbit Anti Rat Cxcl1 Polyclonal Antibody |
|||
CPBT-65101RR | Creative Diagnostics | 0.1 mg | EUR 1057.2 |
CXCL1 antibody (FITC) |
|||
60R-2237 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal CXCL1 antibody (FITC) |
CXCL1/GRO |
|||
EF012822 | Lifescience Market | 96 Tests | EUR 826.8 |
CXCL1/GRO |
|||
E21-597 | EnoGene | 10ug | EUR 411.6 |
Cxcl1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K4368202 | ABM | 1.0 ug DNA | EUR 184.8 |
Cxcl1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K4368203 | ABM | 1.0 ug DNA | EUR 184.8 |
Cxcl1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K4368204 | ABM | 1.0 ug DNA | EUR 184.8 |
CXCL1 antibody (biotin) |
|||
60R-2238 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Rabbit polyclonal CXCL1 antibody (biotin) |
CXCL1 siRNA |
|||
20-abx913248 | Abbexa |
|
|
CXCL1 siRNA |
|||
20-abx913249 | Abbexa |
|
|
CXCL1 siRNA |
|||
20-abx901350 | Abbexa |
|
|
pEGFP- CXCL1 |
|||
PVT10178 | Lifescience Market | 2 ug | EUR 361.2 |
CXCL1 protein |
|||
30R-3156 | Fitzgerald | 50 ug | EUR 308.4 |
Description: Purified recombinant CXCL1 protein |
CXCL1 Peptide |
|||
42-129P | ProSci | 0.1 mg | EUR 405.6 |
Description: (CT) CXCL1 Peptide |
CXCL1 Conjugated Antibody |
|||
C33054 | SAB | 100ul | EUR 476.4 |
Cxcl1 Polyclonal Antibody |
|||
A51950 | EpiGentek |
|
|
CXCL1 Polyclonal Antibody |
|||
A51978 | EpiGentek |
|
|
CXCL1 Chemi-Luminescent ELISA Kit (Mouse) (OKCD03823) |
|||
OKCD03823 | Aviva Systems Biology | 96 Wells | EUR 1232.4 |
Description: Description of target: Has chemotactic activity for neutrophils. Contributes to neutrophil activation during inflammation . Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. KC(5-72) shows a highly enhanced hematopoietic activity.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 15.6 pg/mL |
Mouse Cxcl1/ Growth-regulated alpha protein ELISA Kit |
|||
E0354Mo | Sunlong | 1 Kit | EUR 655.2 |
Mouse Growth regulated alpha protein, Cxcl1 ELISA KIT |
|||
ELI-04012m | Lifescience Market | 96 Tests | EUR 1038 |
GRO alpha (CXCL1) Antibody |
|||
abx018005-100ug | Abbexa | 100 ug | EUR 410.4 |
Gro alpha Antibody / CXCL1 |
|||
RQ4031 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: CXCL1 (Chemokine, CXC motif, Ligand 1), also called GRO1, SCYB1, GROA or MGSA, is a small cytokine belonging to the CXC chemokine family that was previously called GRO1 oncogene, GRO?, KC, Neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-?). In humans, this protein is encoded by the CXCL1 gene. The CXCL1 gene is mapped on 4q13.3. CXCL1 is secreted by human melanoma cells, has mitogenic properties and is implicated in melanoma pathogenesis. It is expressed by macrophages, neutrophils and epithelial cells, and has neutrophil chemoattractant activity. CXCL1 plays a role in spinal cord development by inhibiting the migration of oligodendrocyte precursors and is involved in the processes of angiogenesis, inflammation, wound healing, and tumorigenesis. Signaling through Cxcr2, Cxcl1 inhibited oligodendrocyte precursor migration. The migrational arrest was rapid, reversible, and concentration dependent, and it reflected enhanced cell/substrate interactions. White matter expression of Cxcl1 was temporospatially regulated. Others contribute to aggressive growth selectivity in the lung. Among the lung metastasis signature genes identified, several, including CXCL1, were functionally validated. |
Mouse Growth-Regulated Alpha Protein (CXCL1) ELISA Kit |
|||
abx253956-96tests | Abbexa | 96 tests | EUR 801.6 |
Mouse Growth-Regulated Alpha Protein (CXCL1) ELISA Kit |
|||
20-abx154438 | Abbexa |
|
|
Mouse Growth-Regulated Alpha Protein (CXCL1) ELISA Kit |
|||
abx050043-96tests | Abbexa | 96 tests | EUR 924 |
Mouse Growth-Regulated Alpha Protein (CXCL1) ELISA Kit |
|||
abx574645-96tests | Abbexa | 96 tests | EUR 801.6 |
Mouse CXCL1/GROα(Growth Regulated Oncogene Alpha) ELISA Kit |
|||
EM0003 | FN Test | 96T | EUR 571.5 |
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Mus ;Sensitivity: 9.375pg/ml |
CXCL1 Antibody, HRP conjugated |
|||
1-CSB-PA06097B0Rb | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
Cxcl1 Antibody, HRP conjugated |
|||
1-CSB-PA09217B0Rb | Cusabio |
|
|
Description: A polyclonal antibody against Cxcl1. Recognizes Cxcl1 from Mouse. This antibody is HRP conjugated. Tested in the following application: ELISA |
CXCL1 Antibody, FITC conjugated |
|||
1-CSB-PA06097C0Rb | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
Cxcl1 Antibody, FITC conjugated |
|||
1-CSB-PA09217C0Rb | Cusabio |
|
|
Description: A polyclonal antibody against Cxcl1. Recognizes Cxcl1 from Mouse. This antibody is FITC conjugated. Tested in the following application: ELISA |
CXCL1 Antibody, Biotin conjugated |
|||
1-CSB-PA06097D0Rb | Cusabio |
|
|
Description: A polyclonal antibody against CXCL1. Recognizes CXCL1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Cxcl1 Antibody, Biotin conjugated |
|||
1-CSB-PA09217D0Rb | Cusabio |
|
|
Description: A polyclonal antibody against Cxcl1. Recognizes Cxcl1 from Mouse. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Recombinant Mouse CXCL1/ GRO-alpha Protein, Untagged, E.coli-1mg |
|||
QP1455-1mg | EnQuireBio | 1mg | EUR 3427.2 |
Recombinant Mouse CXCL1/ GRO-alpha Protein, Untagged, E.coli-5ug |
|||
QP1455-5ug | EnQuireBio | 5ug | EUR 163.2 |
Recombinant Mouse CXCL1/ GRO-alpha Protein, Untagged, E.coli-20ug |
|||
QP1455-20ug | EnQuireBio | 20ug | EUR 284.4 |
Mouse Growth Regulated Oncogene Alpha / GROa (CXCL1) CLIA Kit |
|||
abx196070-96tests | Abbexa | 96 tests | EUR 990 |
CXCL1 cloning plasmid |
|||
CSB-CL006239HU-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the CXCL1 gene. |
Recombinant Mouse CXCL1/ MGSA/ NAP-3 Protein, His, E.coli-1mg |
|||
QP8650-ec-1mg | EnQuireBio | 1mg | EUR 2763.6 |
Recombinant Mouse CXCL1/ GRO-alpha Protein, Untagged, E.coli-100ug |
|||
QP1455-100ug | EnQuireBio | 100ug | EUR 588 |
Recombinant Mouse CXCL1/ GRO-alpha Protein, Untagged, E.coli-500ug |
|||
QP1455-500ug | EnQuireBio | 500ug | EUR 2133.6 |
CXCL1 Blocking Peptide |
|||
20-abx061039 | Abbexa |
|
|
CXCL1 Blocking Peptide |
|||
33R-7741 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CXCL1 antibody, catalog no. 70R-10502 |
Recombinant Mouse CXCL1/ MGSA/ NAP-3 Protein, His, E.coli-10ug |
|||
QP8650-ec-10ug | EnQuireBio | 10ug | EUR 326.4 |